C. Looney

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐CD20 monoclonal antibody for the desensitization of candidates for renal transplant

R. Redfield, E. Reed, A. Zachary, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer

D. Danilenko, J. DeVoss, A. Zarrin, 2019, Front. Immunol..

Assessment of Disease‐Related Therapeutic Protein Drug‐Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis

R. Maciuca, J. Kenny, L. Dickmann, 2016, Journal of clinical pharmacology.

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

D. Danilenko, M. Williams, O. Hwang, 2011, British journal of pharmacology.

Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells

D. Danilenko, S. Prabhu, Shan Chung, 2017, British journal of pharmacology.

SUN-374 B-CELL DEPLETION AND RESPONSE IN A RANDOMIZED, CONTROLLED TRIAL OF OBINUTUZUMAB FOR PROLIFERATIVE LUPUS NEPHRITIS

B. Rovin, R. Furie, G. Aroca, 2020 .